Apellis Pharmaceuticals
APLS
APLS
262 hedge funds and large institutions have $3.38B invested in Apellis Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 95 increasing their positions, 93 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
2% more repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 93
0% more funds holding
Funds holding: 262 → 262 (0)
24% less capital invested
Capital invested by funds: $4.43B → $3.38B (-$1.05B)
Holders
262
Holding in Top 10
6
Calls
$128M
Puts
$41.5M
Top Buyers
| 1 | +$72.5M | |
| 2 | +$54.8M | |
| 3 | +$40.7M | |
| 4 |
Morgan Stanley
New York
|
+$36.7M |
| 5 |
JPMorgan Chase & Co
New York
|
+$20.4M |
Top Sellers
| 1 | -$56.3M | |
| 2 | -$51.1M | |
| 3 | -$30.7M | |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$29.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.9M |